CY1107862T1 - Φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα οιστερολης για χρηση στη θεραπεια του καρκινου - Google Patents
Φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα οιστερολης για χρηση στη θεραπεια του καρκινουInfo
- Publication number
- CY1107862T1 CY1107862T1 CY20081100080T CY081100080T CY1107862T1 CY 1107862 T1 CY1107862 T1 CY 1107862T1 CY 20081100080 T CY20081100080 T CY 20081100080T CY 081100080 T CY081100080 T CY 081100080T CY 1107862 T1 CY1107862 T1 CY 1107862T1
- Authority
- CY
- Cyprus
- Prior art keywords
- esterol
- producers
- pharmaceutical compositions
- compositions containing
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940011871 estrogen Drugs 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 230000001076 estrogenic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μία μέθοδο θεραπείας ή πρόληψης των οιστρογόνο-κατεσταλμένων όγκων σε ένα θηλαστικό, με την αναφερθείσα μέθοδο να περιλαμβάνει την χορήγηση μιας θεραπευτικά αποτελεσματικής ποσότητας ενός οιστρογονικού συστατικού στο αναφερθέν θηλαστικό, όπου το οιστρογονικό συστατικό έχει επιλεγεί από την ομάδα, η οποία αποτελείται από: ουσίες που αντιπροσωπεύονται από τον ακόλουθο χημικό τύπο (I), στον οποίο χημικό τύπο οι R1, R2, R3, R4, είναι ανεξάρτητα, ένα άτομο υδρογόνου, μία υδροξυλική ομάδα ή μία αλκόξυ ομάδα με 1-5 άτομα άνθρακα, πρόδρομα μόρια ικανά να απελευθερώνουν την ουσία σύμφωνα με τον χημικό τύπο που αναφέρθηκε πιο πάνω όταν χρησιμοποιηθούν στην παρούσα μέθοδο, και μίγματα μιας ή περισσότερων εκ των ουσιών και/ή πρόδρομων μορίων που αναφέρθηκαν πιο πάνω. Το οιστρογονικό συστατικό σύμφωνα με την εφεύρεση είναι ιδιαιτέρως χρήσιμο στην θεραπεία ή τη πρόληψη του ορθοκολικού και του καρκίνο του προστάτη και, αντίθετα με τα οιστρογόνα που χρησιμοποιούνται συνήθως, δεν ενισχύει ταυτόχρονα τον κίνδυνο εμφάνισης οιστρογόνο-διεγερμένων καρκίνων, όπως είναι για παράδειγμα ο καρκίνος του μαστού.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02079414 | 2002-10-23 | ||
| EP03759076A EP1556058B1 (en) | 2002-10-23 | 2003-10-23 | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107862T1 true CY1107862T1 (el) | 2013-06-19 |
Family
ID=32116285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100080T CY1107862T1 (el) | 2002-10-23 | 2008-01-18 | Φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα οιστερολης για χρηση στη θεραπεια του καρκινου |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8987240B2 (el) |
| EP (1) | EP1556058B1 (el) |
| CN (1) | CN100528167C (el) |
| AT (1) | ATE380552T1 (el) |
| AU (1) | AU2003274823A1 (el) |
| CA (1) | CA2503549C (el) |
| CY (1) | CY1107862T1 (el) |
| DE (1) | DE60318092T2 (el) |
| DK (1) | DK1556058T3 (el) |
| ES (1) | ES2298570T3 (el) |
| PT (1) | PT1556058E (el) |
| SI (1) | SI1556058T1 (el) |
| WO (1) | WO2004037269A1 (el) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE382356T1 (de) * | 2002-07-12 | 2008-01-15 | Pantarhei Bioscience Bv | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung |
| PT1556058E (pt) | 2002-10-23 | 2008-03-20 | Pantarhei Bioscience Bv | Composições farmacêuticas que compreendem derivados do estretol para serem utilizadas no tratamento do cancro |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| HRP20130961T1 (hr) * | 2006-08-25 | 2013-11-22 | Janssen Oncology, Inc. | Kombinacije za tretman raka |
| CA2691654C (en) * | 2007-06-21 | 2016-06-07 | Pantarhei Bioscience B.V. | Treatment of meconium aspiration syndrome with estrogens |
| WO2012164096A1 (en) | 2011-06-01 | 2012-12-06 | Estetra S.A. | Process for the production of estetrol intermediates |
| RS55293B1 (sr) | 2011-06-01 | 2017-03-31 | Estetra Sprl | Postupak proizvodnje intermedijara estetrola |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| WO2013071214A1 (en) * | 2011-11-10 | 2013-05-16 | Sri International | Synergistic anti-cancer activity of sr16388 with anti-mitotic drugs |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| PE20180398A1 (es) | 2015-06-18 | 2018-02-28 | Mithra Pharmaceuticals S A | Unidad de dosificacion orodispersable que contiene un componente estetrol |
| SI3310333T1 (sl) | 2015-06-18 | 2020-08-31 | Estetra Sprl | Orodisperzibilna enota odmerka, ki vsebuje komponento estetrola |
| PL3310345T3 (pl) | 2015-06-18 | 2021-10-18 | Estetra Sprl | Ulegająca rozpadowi w jamie ustnej tabletka zawierająca estetrol |
| RS61777B1 (sr) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Oralno-disperzibilna tableta koja sadrži estetrol |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | ステロイドホルモン薬学的組成物 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| CN109640991A (zh) | 2016-07-29 | 2019-04-16 | 詹森药业有限公司 | 治疗前列腺癌的方法 |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| EP3661520B1 (en) * | 2017-08-01 | 2021-12-01 | Fund SA | Adjuvant therapy for use in prostate cancer treatment |
| CN109718198A (zh) * | 2017-10-30 | 2019-05-07 | 浙江京新药业股份有限公司 | 一种治疗前列腺癌的注射剂及其制备方法 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| HUP2400151A1 (hu) | 2024-02-28 | 2025-09-28 | Richter Gedeon Nyrt | Ösztetrol-monohidrát kristályosítási eljárás |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3440320A (en) * | 1964-06-18 | 1969-04-22 | Mortimer D Sackler | Chelated suppository and method of using same |
| US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| DE2426779A1 (de) | 1974-05-31 | 1975-12-18 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
| DE2336433A1 (de) | 1973-07-13 | 1975-04-03 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
| DE2336434A1 (de) | 1973-07-13 | 1975-04-17 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
| US4722941A (en) * | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
| US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
| US4573996A (en) * | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
| US4624665A (en) * | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
| US4937238A (en) * | 1986-03-04 | 1990-06-26 | The Board Of Regents Of The University Of Nebraska | Prevention of mammary carcinoma |
| US4762717A (en) * | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
| US5223261A (en) * | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
| US5043331A (en) | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
| US5130137A (en) * | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
| JPH04235171A (ja) | 1990-07-26 | 1992-08-24 | Sumitomo Chem Co Ltd | スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤 |
| US5063507A (en) * | 1990-09-14 | 1991-11-05 | Plains Cotton Cooperative Association | Goods database employing electronic title or documentary-type title |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| US5340586A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
| US5895783A (en) | 1993-07-16 | 1999-04-20 | Schering Aktiengesellschaft | Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor |
| NL9301562A (nl) * | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| WO1996003929A1 (en) | 1994-08-04 | 1996-02-15 | Biex, Inc. | Method for prediction of premature delivery using estetrol (e4) as an indicator |
| DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| DE69831241T2 (de) | 1997-06-20 | 2006-03-23 | Akzo Nobel N.V. | Gonadotropin freisetzendes Hormon Antagonist |
| DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| US6214815B1 (en) * | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
| US6291456B1 (en) * | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| AU5137900A (en) | 1999-05-28 | 2000-12-18 | University Of Cincinnati, The | Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use |
| WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
| CA2389666A1 (en) * | 1999-11-01 | 2001-05-10 | Torcan Chemical Ltd. | Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts |
| CO5271709A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
| AU2001259847B9 (en) | 2000-05-12 | 2006-08-10 | Oregon Health And Science University | Method of treating immune pathologies with low dose estrogen |
| AU2002213198A1 (en) * | 2000-10-11 | 2002-04-22 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| MXPA03006958A (es) * | 2001-02-05 | 2003-11-18 | Upjohn Co | Composicion para administracion rectal de farmaco antibacterial de oxazolidinona. |
| AU2002240949A1 (en) * | 2001-03-21 | 2002-10-03 | Schering Aktiengesellschaft | Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy |
| US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
| EP1293210B1 (en) | 2001-05-23 | 2003-11-19 | Pantarhei Bioscience B.V. | Means and method for hormonal contraception |
| DK1390040T3 (da) * | 2001-05-18 | 2007-04-23 | Pantarhei Bioscience Bv | Farmaceutisk præparat til anvendelse i hormonerstatningsterapi |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| EP1390041B1 (en) | 2001-05-23 | 2009-11-25 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| WO2002094277A1 (en) | 2001-05-23 | 2002-11-28 | Pantarhei Bioscience B.V. | Means and method for hormonal contraception |
| DK1390042T3 (da) | 2001-05-23 | 2008-03-31 | Pantarhei Bioscience Bv | System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse |
| GB0112617D0 (en) | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| US6790979B2 (en) * | 2002-04-17 | 2004-09-14 | University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| PT1556058E (pt) | 2002-10-23 | 2008-03-20 | Pantarhei Bioscience Bv | Composições farmacêuticas que compreendem derivados do estretol para serem utilizadas no tratamento do cancro |
-
2003
- 2003-10-23 PT PT03759076T patent/PT1556058E/pt unknown
- 2003-10-23 DE DE60318092T patent/DE60318092T2/de not_active Expired - Lifetime
- 2003-10-23 EP EP03759076A patent/EP1556058B1/en not_active Expired - Lifetime
- 2003-10-23 CA CA2503549A patent/CA2503549C/en not_active Expired - Lifetime
- 2003-10-23 DK DK03759076T patent/DK1556058T3/da active
- 2003-10-23 AT AT03759076T patent/ATE380552T1/de active
- 2003-10-23 CN CNB2003801074356A patent/CN100528167C/zh not_active Expired - Lifetime
- 2003-10-23 US US10/532,320 patent/US8987240B2/en active Active
- 2003-10-23 SI SI200331061T patent/SI1556058T1/sl unknown
- 2003-10-23 WO PCT/NL2003/000718 patent/WO2004037269A1/en active IP Right Grant
- 2003-10-23 AU AU2003274823A patent/AU2003274823A1/en not_active Abandoned
- 2003-10-23 ES ES03759076T patent/ES2298570T3/es not_active Expired - Lifetime
-
2008
- 2008-01-18 CY CY20081100080T patent/CY1107862T1/el unknown
-
2015
- 2015-02-12 US US14/621,267 patent/US9561238B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2298570T3 (es) | 2008-05-16 |
| US20060247221A1 (en) | 2006-11-02 |
| EP1556058B1 (en) | 2007-12-12 |
| WO2004037269A1 (en) | 2004-05-06 |
| AU2003274823A1 (en) | 2004-05-13 |
| DE60318092T2 (de) | 2008-11-27 |
| DE60318092D1 (de) | 2008-01-24 |
| SI1556058T1 (sl) | 2008-02-29 |
| DK1556058T3 (da) | 2008-03-03 |
| CA2503549C (en) | 2012-07-10 |
| ATE380552T1 (de) | 2007-12-15 |
| CA2503549A1 (en) | 2004-05-06 |
| US20150150887A1 (en) | 2015-06-04 |
| CN1732007A (zh) | 2006-02-08 |
| US9561238B2 (en) | 2017-02-07 |
| PT1556058E (pt) | 2008-03-20 |
| CN100528167C (zh) | 2009-08-19 |
| EP1556058A1 (en) | 2005-07-27 |
| US8987240B2 (en) | 2015-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107862T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα οιστερολης για χρηση στη θεραπεια του καρκινου | |
| AU6045398A (en) | Androgen synthesis inhibitors | |
| IL243812A0 (en) | Compounds of diarylhydantoin | |
| SG170809A1 (en) | Diarylthiohydantoin compounds | |
| YU596A (sh) | Estrogen agonisti/antagonisti | |
| PH12013500123A1 (en) | Hemiasterlin derivatives and uses thereof | |
| WO2004058171A3 (en) | Antibodies against gpr64 and uses thereof | |
| MXPA04002593A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumor. | |
| PL367682A1 (en) | Dolastatin 10 derivatives | |
| MXPA05009885A (es) | Nuevas triazolonas fusionadas y los usos de las mismas. | |
| MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
| PT1255537E (pt) | Inibidores da proteina farnesil transferase para tratar cancro da mama | |
| WO2006113483A3 (en) | Methods and compositions for treating or preventing cancer | |
| GB2375534B (en) | Anti-cancer compounds | |
| ATE413180T1 (de) | Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs | |
| TW200510367A (en) | Novel lapachone compounds, their preparation, and the use thereof | |
| MXPA05000781A (es) | Compuesto antitumor y usos terapeuticos del mismo. | |
| WO2003106384A3 (en) | NOVEL BORIC CHALCONE DERIVATIVES AND USES THEREOF | |
| MXPA05009480A (es) | Metodos y composiciones para la sintesis enzimatica de gangliosidos. | |
| YU21404A (sh) | Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka | |
| EA200200313A1 (ru) | Применение доцетаксела для лечения печеночно-клеточного рака | |
| GB0215526D0 (en) | Anticancer compounds | |
| AR024907A1 (es) | Uso de inhibidores de la produccion y/o accion de la il-18 y composiciones farmaceuticas formuladas con dichos inhibidores para el tratamiento demetastasis de tumores. | |
| EA200600992A1 (ru) | Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение | |
| WO2002020000A3 (en) | Combined estrogen blockade of the breast with exemestane and raloxifene |